324 related articles for article (PubMed ID: 28559271)
1. Prevalence of Invasive Infections Due to Carbapenem-Resistant Enterobacteriaceae among Adult Patients in U.S. Hospitals.
Lodise T; Ye MJ; Zhao Q
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559271
[TBL] [Abstract][Full Text] [Related]
2. Carbapenem-resistant Enterobacteriaceae in patients with bacteraemia at tertiary hospitals in South Africa, 2015 to 2018.
Perovic O; Ismail H; Quan V; Bamford C; Nana T; Chibabhai V; Bhola P; Ramjathan P; Swe Swe-Han K; Wadula J; Whitelaw A; Smith M; Mbelle N; Singh-Moodley A;
Eur J Clin Microbiol Infect Dis; 2020 Jul; 39(7):1287-1294. PubMed ID: 32124106
[TBL] [Abstract][Full Text] [Related]
3. Carbapenemase-Producing Enterobacteriaceae and Nonfermentative Bacteria, the Philippines, 2013-2016.
Velasco JM; Valderama MT; Peacock T; Warawadee N; Nogrado K; Navarro FC; Chua D; Apichai S; Sirigade R; Macareo LR; Swierczewski B
Emerg Infect Dis; 2017 Sep; 23(9):1597-1598. PubMed ID: 28820383
[TBL] [Abstract][Full Text] [Related]
4. Factors associated to prevalence and treatment of carbapenem-resistant Enterobacteriaceae infections: a seven years retrospective study in three tertiary care hospitals.
Pang F; Jia XQ; Zhao QG; Zhang Y
Ann Clin Microbiol Antimicrob; 2018 Mar; 17(1):13. PubMed ID: 29571291
[TBL] [Abstract][Full Text] [Related]
5. Carbapenem-Resistant and Extended-Spectrum β-Lactamase-Producing Enterobacterales in Children, United States, 2016-2020.
Grome HN; Grass JE; Duffy N; Bulens SN; Ansari U; Campbell D; Lutgring JD; Gargis AS; Masters T; Kent AG; McKay SL; Smith G; Wilson LE; Vaeth E; Evenson B; Dumyati G; Tsay R; Phipps E; Flores K; Wilson CD; Czaja CA; Johnston H; Janelle SJ; Lynfield R; O'Malley S; Vagnone PS; Maloney M; Nadle J; Guh AY
Emerg Infect Dis; 2024 Jun; 30(6):1104-1114. PubMed ID: 38781979
[TBL] [Abstract][Full Text] [Related]
6. Carbapenem-Resistant Enterobacteriaceae: An update narrative review from Saudi Arabia.
Alotaibi F
J Infect Public Health; 2019; 12(4):465-471. PubMed ID: 31060974
[TBL] [Abstract][Full Text] [Related]
7. Carbapenem-heteroresistance among isolates of the Enterobacter cloacae complex: is it a real concern?
da Silva AEB; Martins AF; Nodari CS; Magagnin CM; Barth AL
Eur J Clin Microbiol Infect Dis; 2018 Jan; 37(1):185-186. PubMed ID: 29170902
[No Abstract] [Full Text] [Related]
8. Occurrence of carbapenemase-producing Enterobacteriaceae in Togo, West Africa.
Dossim S; Bonnin RA; Salou M; Tanga K; Godonou V; Dagnra AY; Prince David M; Naas T; Dortet L
Int J Antimicrob Agents; 2019 Apr; 53(4):530-532. PubMed ID: 30476571
[No Abstract] [Full Text] [Related]
9. Rapid detection of carbapenemase activity of Enterobacteriaceae isolated from positive blood cultures by MALDI-TOF MS.
Yu J; Liu J; Li Y; Yu J; Zhu W; Liu Y; Shen L
Ann Clin Microbiol Antimicrob; 2018 May; 17(1):22. PubMed ID: 29776363
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with carriage of carbapenem-non-susceptible Enterobacteriaceaein North-Eastern France and outcomes of infected patients.
Muggeo A; Guillard T; Barbe C; Thierry A; Bajolet O; Vernet-Garnier V; Limelette A; Brasme L; De Champs C;
J Antimicrob Chemother; 2017 May; 72(5):1496-1501. PubMed ID: 28158526
[TBL] [Abstract][Full Text] [Related]
11. Risk factors and outcomes associated with the isolation of polymyxin B and carbapenem-resistant Enterobacteriaceae spp.: A case-control study.
Teo JQ; Chang CW; Leck H; Tang CY; Lee SJ; Cai Y; Ong RT; Koh TH; Tan TT; Kwa AL
Int J Antimicrob Agents; 2019 May; 53(5):657-662. PubMed ID: 30880229
[TBL] [Abstract][Full Text] [Related]
12. Evidence from a New York City hospital of rising incidence of genetically diverse carbapenem-resistant Enterobacter cloacae and dominance of ST171, 2007-14.
Gomez-Simmonds A; Hu Y; Sullivan SB; Wang Z; Whittier S; Uhlemann AC
J Antimicrob Chemother; 2016 Aug; 71(8):2351-3. PubMed ID: 27118776
[No Abstract] [Full Text] [Related]
13. The outcome of treating ESBL infections with carbapenems vs. non carbapenem antimicrobials.
Trivedi M; Patel V; Soman R; Rodriguez C; Singhal T
J Assoc Physicians India; 2012 Aug; 60():28-30. PubMed ID: 23405518
[TBL] [Abstract][Full Text] [Related]
14. Carbapenemases: The never-ending story.
Martínez-Martínez L
Enferm Infecc Microbiol Clin (Engl Ed); 2019 Feb; 37(2):73-75. PubMed ID: 30591386
[No Abstract] [Full Text] [Related]
15. Prevalence of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Bahrain.
Bindayna KM; Senok AC; Jamsheer AE
J Infect Public Health; 2009; 2(3):129-35. PubMed ID: 20701872
[TBL] [Abstract][Full Text] [Related]
16. The epidemiology and risk factor of carbapenem-resistant enterobacteriaceae colonization and infections: Case control study in a single institute in Japan.
Asai N; Sakanashi D; Suematsu H; Kato H; Hagihara M; Nishiyama N; Koizumi Y; Yamagishi Y; Mikamo H
J Infect Chemother; 2018 Jul; 24(7):505-509. PubMed ID: 29548627
[TBL] [Abstract][Full Text] [Related]
17. Successful containment of carbapenem-resistant Enterobacteriaceae by strict contact precautions without active surveillance.
Kim NH; Han WD; Song KH; Seo HK; Shin MJ; Kim TS; Park KU; Ahn S; Yoo JS; Kim ES; Kim HB
Am J Infect Control; 2014 Dec; 42(12):1270-3. PubMed ID: 25465255
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and mechanisms of resistance to carbapenems in Enterobacteriaceae isolates from 24 hospitals in Belgium.
Huang TD; Berhin C; Bogaerts P; Glupczynski Y;
J Antimicrob Chemother; 2013 Aug; 68(8):1832-7. PubMed ID: 23557926
[TBL] [Abstract][Full Text] [Related]
19. The threat of carbapenem-resistant Enterobacteriaceae in Lebanon: an update on the regional and local epidemiology.
El-Herte RI; Kanj SS; Matar GM; Araj GF
J Infect Public Health; 2012 Jun; 5(3):233-43. PubMed ID: 22632597
[TBL] [Abstract][Full Text] [Related]
20. Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae.
Lee YR; Baker NT
Eur J Clin Microbiol Infect Dis; 2018 Aug; 37(8):1411-1419. PubMed ID: 29675787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
